Brokers Offer Predictions for Kura Oncology FY2029 Earnings

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Investment analysts at Brookline Capital Management issued their FY2029 EPS estimates for shares of Kura Oncology in a research report issued to clients and investors on Monday, January 6th. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings per share of $12.19 for the year. The consensus estimate for Kura Oncology's current full-year earnings is ($2.44) per share.

KURA has been the subject of several other research reports. HC Wainwright boosted their price objective on Kura Oncology from $32.00 to $37.00 and gave the company a "buy" rating in a research report on Thursday, November 21st. Cantor Fitzgerald reissued an "overweight" rating on shares of Kura Oncology in a report on Monday, December 9th. StockNews.com cut shares of Kura Oncology from a "hold" rating to a "sell" rating in a research report on Wednesday, November 20th. Scotiabank cut their target price on Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating on the stock in a research note on Wednesday. Finally, TD Cowen reaffirmed a "buy" rating on shares of Kura Oncology in a research report on Thursday, November 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $27.38.

Kura Oncology Trading Down 4.8 %

Shares of NASDAQ:KURA traded down $0.39 on Thursday, reaching $7.78. 2,097,375 shares of the company traded hands, compared to its average volume of 1,500,322. Kura Oncology has a 52 week low of $7.70 and a 52 week high of $24.17. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The business's 50-day simple moving average is $11.93 and its 200 day simple moving average is $17.01. The stock has a market capitalization of $605.00 million, a P/E ratio of -3.30 and a beta of 0.81.

Hedge Funds Weigh In On Kura Oncology

Institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. increased its holdings in shares of Kura Oncology by 0.8% during the third quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company's stock valued at $7,997,000 after acquiring an additional 3,092 shares in the last quarter. Franklin Resources Inc. increased its stake in Kura Oncology by 1.5% during the 3rd quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company's stock valued at $28,687,000 after purchasing an additional 23,113 shares in the last quarter. Geode Capital Management LLC raised its holdings in Kura Oncology by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock worth $34,798,000 after buying an additional 41,535 shares during the last quarter. Barclays PLC raised its holdings in Kura Oncology by 104.5% in the third quarter. Barclays PLC now owns 165,484 shares of the company's stock worth $3,234,000 after buying an additional 84,563 shares during the last quarter. Finally, Jane Street Group LLC lifted its stake in shares of Kura Oncology by 36.7% in the third quarter. Jane Street Group LLC now owns 126,085 shares of the company's stock worth $2,464,000 after buying an additional 33,848 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.